Efficacy of mometasone furoate and fluticasone furoate on persistent allergic rhinoconjunctivitis

W Hamizan Aneeza, Salina Husain, Roslenda Abdul Rahman, Dexter Van Dort, Asma Abdullah, Balwant S Gendeh, W Hamizan Aneeza, Salina Husain, Roslenda Abdul Rahman, Dexter Van Dort, Asma Abdullah, Balwant S Gendeh

Abstract

Allergic rhinoconjunctivitis denotes both nasal and ocular manifestation of allergy, which may be solely treated with intranasal steroid. This study compares the efficacy of mometasone furoate nasal spray (NS) and fluticasone furoate NS in treatment of allergic rhinoconjunctivitis. The secondary objective is to study the severity of baseline ocular symptoms in allergic rhinoconjunctivitis. Seventy-eight patients with allergic rhinoconjunctivitis were assessed subjectively and objectively using twice-daily symptom scores for nasal (reflective total nasal symptom score [rTNSS] and instantaneous TNSS [iTNSS]) and ocular (reflective total ocular symptom score [rTOSS] and instantaneous TOSS [iTOSS]) symptoms, rhinoconjunctivitis quality-of-life questionnaires (RQOLQs), and acoustic rhinometry. All measurements were taken at baseline and at 4 and 8 weeks of treatment. Sixty-three patients who were randomized into the mometasone furoate group (n = 36) and the fluticasone furoate group (n = 27) completed the study. Seventy-six percent of patients had mild ocular symptoms, 20.5% had moderate symptoms, and only 2.6% had severe symptoms at baseline based on the iTOSS; 65.1% had mild nasal symptoms and 3% had severe nasal symptoms. There was significant reduction in the symptom scores after 1 week (p < 0.05). Both groups had significant improvement in RQOLQ scores after 1 month, which further improved at 2 months (p < 0.05). The nasal dimensions also improved in both groups (p < 0.05) but there was no statistically significant difference between groups. Both mometasone furoate and fluticasone furoate are effective as single-modality treatment of allergic rhinoconjunctivitis. The majority of patients manifest mild ocular symptoms that may be solely treated with intranasal steroids.

Keywords: Allergic rhinoconjunctivitis; fluticasone furoate; intranasal steroids; mometasone furoate; ocular symptoms; perennial allergic rhinitis.

Conflict of interest statement

The authors have no conflicts of interest to declare pertaining to this article

Figures

Figure 1.
Figure 1.
Comparison between instantaneous total nasal symptom score (iTNSS) and instantaneous total ocular symptom score (iTOSS) after treatment with mometasone furoate nasal spray (NS) or fluticasone furoate NS. There was no statistical difference in efficacy between the two intranasal steroids.

References

    1. Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108:S147–S334, 2001
    1. Ng ML, Warlow RS, Chrishanthan N, et al. Preliminary criteria for the defnition of allergic rhinitis: A systematic evaluation of clinical parameters in a disease cohort (I). Clin Exp Allergy 30:1314–1331, 2000
    1. Canonica GW, Mullol J, Pradalier A, Didier A. Patient perceptions of allergic rhinitis and quality of life. Findings from a survey conducted in Europe and the United States. World Allergy Organization 1:138–144, 2008
    1. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1–-S84, 2008
    1. Brunton SA, Fromer LM. Treatment options on management of perennial allergic rhinitis with focus on intranasal corticosteroid. South Med J 100:701–708, 2007
    1. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 317:1624–1629, 1998
    1. Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 100:272–279, 2008
    1. Bernstein DI, Levy AL, Hampel FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 34:952–957, 2004
    1. Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 119:1430–1437, 2007
    1. Baroody FM, Logethehs H., Vishunnoth S., et al. Effect of intranasal fluticasone furoate and intraocular olopatadine on nasal and ocular allergen-induced symptoms. Am J Rhinol Allergy 27:48–53, 2013
    1. Nathan RA, Berger W, Yang W, et al. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 100:497–505, 2008
    1. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 104:364–369, 1999
    1. Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy 62:17–25, 2007
    1. Wuthrich B, Brignoli R, Canevascini M, Gerber M. Epidemiological survey in hay fever patients: Symptom prevalence and severity and influence on patient management. Schweiz Med Wochenschr 128:139–143, 1998
    1. Gendeh BS, Mujahid SH, Murad S, Rizal M. Atopic sensitization of children with rhinitis in Malaysia. Med J Malaysia 59:522–529, 2004
    1. Vasar M, Houle PA, Douglass JA, et al. Fluticasone furoate nasal spray: Effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc 29:313–321, 2008
    1. Jacobs R, Martin B, Hampel F, et al. Effectiveness of fluticasone furoate 110 μg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen. Curr Med Res Opin 25:1393–1401, 2009
    1. Scadding G, Richards D, Price M. Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis. Clin Otolaryngol Allied Sci 25:551–557, 2000
    1. Bousquet J, Knani J, Hejjaoui A, et al. Heterogeneity of atopy. I. Clinical and immunologic characteristics of patients allergic to cypress pollen. Allergy 48:183–188, 1993
    1. Bielory L, Katelaris C, Lightman S, Naclerio RM. Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. MedGenMed 9:35, 2007
    1. Hong J, Bielory B, Rosenberg JL, Bielory L. Efficacy of intranasal corticosteroids for the ocular symptoms of allergic rhinitis: A systematic review. Allergy Asthma Proc 32:22–35, 2011
    1. Meltzer EO, Shekar T, Teper AA. Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis. Allergy Asthma Proc 32:159–167, 2011
    1. Bielory L, Chun Y, Bielory BP, Canonica GW. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: A meta-analysis. Allergy 66:686–693, 2011
    1. Maspero JF, Walters RD, Wu W, et al. An integrated analysis of the efficacy of fluticasone furoate nasal spray on individual nasal and ocular symptoms of seasonal allergic rhinitis. Allergy Asthma Proc 31:483–492, 2010
    1. Villa E, Magnoni MS, Micheli D, Canonica GW. A review of the use of fluticasone furoate since its launch. Expert Opin Pharmacother 12:2107–2117, 2011
    1. Bielory L, Georges G, Gross G. Treating the ocular symptoms of seasonal allergic rhinitis with triamcinolone acetonide aqueous nasal spray. Ann Allergy Asthma Immunol 103:80–81, 2009
    1. van Bavel JH, Ratner PH, Amar NJ, et al. Efficacy and safety of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 33:386–396, 2012
    1. Ratner PH, Wingertzahn MA, van Bavel JH, et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 118:1142–1148, 2006
    1. Krouse JH, Roland PS, Marple BF, et al. Optimal duration of allergic rhinitis clinical trials. Otolaryngol Head Neck Surg 133:467–487, 2005
    1. Rosenwasser LJ, Mahr T, Abelson MB, et al. (Eds). A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. Allergy Asthma Proc 29:644–653, 2008
    1. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 28:3–9, 2007
    1. Lu D, Zhao Y, Zheng Y, et al. Evaluation of quality of life questionnaires for adult patients with moderate to severe allergic rhinitis. Am J Otolaryngol 32:494–498, 2010
    1. Salapatek AM, Patel P, Gopalan G, Varghese ST. Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients. Am J Rhinol Allergy 24:433–438, 2010

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe